...
机译:Why does survival of hepatocellular carcinoma patients remain so low? Key stumbling blocks and questions in preclinical and clinical development
IRCCS San Raffaele Sci Inst Hosp,Univ Vita Salute San Raffaele;
Hepatocellular carcinoma; systemic therapy; locoregional treatment; combination therapy; antiangiogenic drugs; immunotherapy; biomarkers; clinical trials; ATEZOLIZUMAB PLUS BEVACIZUMAB; TRANSARTERIAL CHEMOEMBOLIZATION; DOUBLE-BLIND; 1ST-LINE TREATMENT; PHASE-III; NON-INFERIORITY; SORAFENIB; LENVATINIB; THERAPY; COMBINATION;